HOME >> BIOLOGY >> NEWS
Phase 3 psoriatic arthritis data for ENBREL (etanercept) announced at a national scientific meeting

is the only tumor necrosis factor (TNF) inhibitor approved for use without methotrexate. It is also the only TNF inhibitor approved for use as a first-line therapy for RA.

ENBREL acts by binding TNF, one of the dominant cytokines or regulatory proteins that play an important role in both normal immune function and the cascade of reactions that cause the inflammatory process of RA and psoriatic arthritis. ENBREL competitively inhibits binding of TNF molecules to the TNF receptor sites. The binding of ENBREL to TNF renders the bound TNF biologically inactive, resulting in significant reduction in inflammatory activity.

SINCE THE PRODUCT WAS FIRST INTRODUCED, SERIOUS INFECTIONS, SOME INVOLVING DEATH, HAVE BEEN REPORTED IN PATIENTS USING ENBREL. MANY OF THESE INFECTIONS OCCURRED IN PATIENTS WHO WERE PRONE TO INFECTIONS, SUCH AS THOSE WITH ADVANCED OR POORLY CONTROLLED DIABETES. RARE CASES OF TUBERCULOSIS HAVE ALSO BEEN REPORTED. ENBREL SHOULD BE DISCONTINUED IN PATIENTS WITH SERIOUS INFECTIONS. DO NOT START ENBREL IF YOU HAVE AN INFECTION OF ANY TYPE OR IF YOU HAVE AN ALLERGY TO ENBREL OR ITS COMPONENTS. ENBREL SHOULD BE USED WITH CAUTION IN PATIENTS PRONE TO INFECTION. CONTACT YOUR PHYSICIAN IF YOU HAVE ANY QUESTIONS ABOUT ENBREL OR INFECTIONS.

There have been rare reports of serious nervous system disorders such as multiple sclerosis, seizures or inflammation of the nerves of the eyes. Tell your doctor if you have ever had any of these disorders or if you develop them after starting ENBREL. There have also been rare reports of serious blood disorders, some involving death. Contact your doctor immediately if you develop symptoms such as persistent fever, bruising, bleeding, or paleness. It is unclear if ENBREL (etanercept) has caused these nervous system or blood disorders. If your doctor confirms serious blood problems, you may need to stop using ENBREL.

The most frequent adverse events in placebo-controlled clinical trials involvin
'"/>


12-Nov-2001


Page: 1 2 3 4 5

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. OneWorld Health completes enrollment, treatment in Phase III India trial
3. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
4. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
5. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
6. KEPPRA international Phase IV SKATE study results show favourable efficacy
7. Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
8. Phase III, 48-Wk NEAT study results comparing GW433908 to Nelfinavir presented today
9. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
10. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
11. Phase transition in bilayers could affect their performance

Post Your Comments:
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a ... announced that its U.are.U ® 4500 fingerprint ... Eateries, Inc., a San ... chain, to increase security, improve accountability and reduce ... enable instant, non-repudiable identity confirmation for employee sign ...
(Date:6/16/2015)... 2015  With the increasing number and severity of ... concern. The recent compromise of Federal employee data ... authentication within government agencies. HYPR Corp. announced ... (OTP) authenticator, has been submitted for testing and approval ... validation for tamper proofing. The proliferation ...
(Date:6/16/2015)... GOTHENBURG, Sweden , June 16, 2015 ... 2015 from previously communicated that it will amount to at ... 390 MSEK. Due to the rapid increase in market growth ... from the previously communicated guidance that revenue for 2015 will ... 2015 will amount to approximately 2,200 MSEK. Due ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
(Date:7/1/2015)... 1, 2015 InferMed , ... will ... evidence-based clinical s olutions suite   ... information products and services, announced today the acquisition of  InferMed ... (CDS) technology company. InferMed,s Arezzo technology supports clinicians ...
(Date:7/1/2015)...  UCB, a multinational biopharmaceutical company, and Genpact ... designing, transforming, and running intelligent business operations, have ... their close collaboration in driving transformation that achieved ... (GBS) finance organization. The Aecus Innovation ... together effectively to embrace the innovative promise of ...
(Date:6/30/2015)... - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that ... approved the resolutions relating to: (i) a private ... at a price of $2.67 per unit (the ... one common share and 0.075358 common share purchase ... and (ii) the amendment to Resverlogix,s articles to ...
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, ... focused on developing therapeutics that address unmet medical ... George Elston will present at the ... Wednesday, July 8, 2015Time: , 4:45 PM EDTLocation: ... (live & archive): , www.juniperpharma.com, under  ,Investor, ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
Cached News: